The Precision Medicine Company Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies UK-wide online survey of people with IBD confirms strong patient support for AlphaBiomics’ predictive diagnostic RxSelex™. Read more here. The Precision Medicine Company Developing microbiome-based predictive diagnostic and companion therapeutic products to enable safer and more efficacious drug therapies Winner of the 2018 European Innovation Quickfire Challenge (read more)